問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Surgery

更新時間：2023-11-06

陳天華Chen, Tien-Hua
  • Principal Investigator
  • Clinical Trial Experience (year)

  • gcrc@vghtpe.gov.tw

Recruiting Trial

77Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳天華

List

89Cases

2023-03-19 - 2026-03-16

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2022-03-25 - 2025-10-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-08-31 - 2031-02-28

Phase III

A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high risk for relapse and are ineligible for high-dose cisplatin

  • Condition/Disease

    Head and Neck Cancer

  • Test Drug

    Xevinapant (Debio 1143)

Participate Sites
9Sites

Recruiting9Sites

2022-11-30 - 2027-03-31

Phase I/II

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

  • Condition/Disease

    Advanced Solid Tumor、Locally Advanced Solid Tumor、Metastatic Solid Tumor、Head and Neck Squamous Cell Carcinoma HNSCC、HPV-associated Cancers、Neoadjuvant Melanoma 、Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)

  • Test Drug

    TransCon TLR7/8 Agonist (ACP-017)KEYTRUDA

Participate Sites
4Sites

Recruiting4Sites

2022-04-15 - 2023-10-11

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-04-01 - 2025-12-31

Phase I/II

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

  • Condition/Disease

    Malignant Solid Tumor

  • Test Drug

    Gen1042

Participate Sites
7Sites

Recruiting7Sites

2021-11-01 - 2026-08-02

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-11-01 - 2028-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-09-01 - 2023-09-20

Phase I

A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ASP1951

Participate Sites
3Sites

Recruiting3Sites

邱昌芳
China Medical University Hospital

Division of Hematology & Oncology

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB